Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma M Smith

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Plos One|February 26, 2013
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessmentRosemary A Fryer, Timothy J Graham, Emma M Smith, et al.
Disability and Rehabilitation. Assistive Technology|July 28, 2022
Assistive technologies are central to the realization of the Convention on the Rights of Persons with DisabilitiesEmma M Smith, Stephanie Huff, Holly Wescott, et al.
Science Translational Medicine|September 24, 2020
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastomaKarin Hansson, Katarzyna Radke, Kristina Aaltonen, et al.
Blood|October 15, 2010
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBrian A Walker, Christopher P Wardell, Laura Chiecchio, et al.
Haematologica|January 14, 2021
Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34<sup>+</sup> cord blood hematopoietic stem cells using a clinically applicable lentiviral vectorYang Liu, Maria Dahl, Shubhranshu Debnath, et al.
Brain, Behavior, and Immunity|January 18, 2025
Oral vancomycin treatment alters levels of indole derivatives and secondary bile acids modulating the expression of mTOR pathway genes in astrocytes during EAEPaola Bianchimano, Paola Leone, Emma M Smith, et al.
Oncotarget|May 28, 2015
The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathwayEmma M Smith, Lei Zhang, Brian A Walker, et al.
International Journal of Health Policy and Management|November 17, 2020
Assistive Technology Use and Provision During COVID-19: Results From a Rapid Global SurveyEmma M Smith, Maria Luisa Toro Hernandez, Ikenna D Ebuenyi, et al.
Iscience|November 2, 2023
Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAEPaola Bianchimano, Kacper Iwanowski, Emma M Smith, et al.
Molecular Cancer Therapeutics|April 18, 2009
Aminopeptidase inhibition as a targeted treatment strategy in myelomaHannah E Moore, Emma L Davenport, Emma M Smith, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Plos One|February 26, 2013
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessmentRosemary A Fryer, Timothy J Graham, Emma M Smith, et al.
Disability and Rehabilitation. Assistive Technology|July 28, 2022
Assistive technologies are central to the realization of the Convention on the Rights of Persons with DisabilitiesEmma M Smith, Stephanie Huff, Holly Wescott, et al.
Science Translational Medicine|September 24, 2020
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastomaKarin Hansson, Katarzyna Radke, Kristina Aaltonen, et al.
Blood|October 15, 2010
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBrian A Walker, Christopher P Wardell, Laura Chiecchio, et al.
Haematologica|January 14, 2021
Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34<sup>+</sup> cord blood hematopoietic stem cells using a clinically applicable lentiviral vectorYang Liu, Maria Dahl, Shubhranshu Debnath, et al.
Brain, Behavior, and Immunity|January 18, 2025
Oral vancomycin treatment alters levels of indole derivatives and secondary bile acids modulating the expression of mTOR pathway genes in astrocytes during EAEPaola Bianchimano, Paola Leone, Emma M Smith, et al.
Oncotarget|May 28, 2015
The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathwayEmma M Smith, Lei Zhang, Brian A Walker, et al.
International Journal of Health Policy and Management|November 17, 2020
Assistive Technology Use and Provision During COVID-19: Results From a Rapid Global SurveyEmma M Smith, Maria Luisa Toro Hernandez, Ikenna D Ebuenyi, et al.
Iscience|November 2, 2023
Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAEPaola Bianchimano, Kacper Iwanowski, Emma M Smith, et al.
Molecular Cancer Therapeutics|April 18, 2009
Aminopeptidase inhibition as a targeted treatment strategy in myelomaHannah E Moore, Emma L Davenport, Emma M Smith, et al.
Pageof 8